2025年1月1日至2025年12月31日。 2025年年度业绩预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 证券代码：688185 证券简称：康希诺 公告编号：2026-002 康希诺生物股份公司 （一）业绩预告期间 （二）业绩预告情况 1、经康希诺生物股份公司（以下简称"公司"）财务部门初步测算，预计2025年年度（以下简称"报告 期"）实现营业收入104,000.00万元到108,000.00万元，与上年同期相比，将增加19,366.19万元到 23,366.19万元，同比增长22.88%到27.61%。 2、预计2025年年度实现归属于母公司所有者的净利润为2,450.00万元到2,900.00万元，与上年同期相 比，将实现扭亏为盈。 3、预计2025年年度实现归属于母公司所有者扣除非经常性损益后净利润为-9,100.00万元到-9,600.00万 元。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 公司2024年年度实现营业收入为84,633.81万元，利润总额为 ...

证券日报网讯 1月27日，生物股份发布公告称，公司于2026年1月26日接到股东内蒙古金宇生物控股有 限公司函告，获悉其将所持有的本公司7，420，000股无限售流通股股票质押给浙商证券股份有限公 司，并办理完成了证券质押相关手续。 （编辑 任世碧） ...

（记者 王瀚黎） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 每经AI快讯，生物股份1月27日晚间发布公告称，内蒙古金宇生物控股有限公司持有金宇生物技术股份 有限公司股份约1.25亿股，占公司总股本的11.29%。本次股份质押后，其累计质押公司股份数量为3442 万股，占生物控股持有公司股份数量的27.43%。 ...

Market Overview - The animal health sector experienced a decline of 2.78% on January 27, with Huisheng Biological leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Key stocks in the animal health sector showed varied performance, with the following notable changes: - Huisheng Biological (300871) closed at 29.89, down 8.37% with a trading volume of 376,900 shares and a transaction value of 1.148 billion [2] - Other significant declines included: - ST Lvkang (002868) down 3.86% to 35.40 [1] - Kexin Biological (688526) down 3.88% to 17.10 [1] - Haili Biological (603718) down 4.13% to 6.73 [1] Capital Flow - The animal health sector saw a net outflow of 45.7033 million from institutional investors, while retail investors experienced a net outflow of 59.3359 million [2] - Conversely, speculative funds recorded a net inflow of 105 million [2] Individual Stock Capital Flow - Notable capital flow for specific stocks included: - ST Lvkang (002868) had a net inflow of 29.8876 million from institutional investors, but a net outflow of 40.6641 million from speculative funds [3] - Zhongmu Co. (600195) saw a net inflow of 21.2767 million from institutional investors, with a significant net outflow of 66.5383 million from retail investors [3] - Jinhe Biological (002688) had a net inflow of 19.2937 million from institutional investors, but also faced a net outflow from retail investors [3]

证券代码：600201 证券简称：生物股份 公告编号：临 2026-002 金宇生物技术股份有限公司 关于股东股份质押的公告 内蒙古金宇生物控股有限公司（以下简称"生物控股"）持有金宇生物技 术股份有限公司（以下简称"本公司"、"公司"）股份 125,474,300 股， 占本公司总股本的 11.29%。本次股份质押后，其累计质押本公司股份数 量为 34,420,000 股，占生物控股持有本公司股份数量的 27.43 %。 一、公司股份质押情况 公司于 2026 年 1 月 26 日接到股东生物控股函告，获悉其将所持有的本公司 7,420,000 股无限售流通股股票质押给浙商证券股份有限公司，并办理完成了证 券质押相关手续，具体事项如下： | 股东 | 是否为 | 本次展期/ | 是否为限 | 是否补 | 质押 | | 原质押 | | 展期后到 | | 占其所 持股份 | 占公司 总股本 | 质押 融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 控股股 东 | 质 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 第七十五条 本规则所称"以上""内"含本数；"过""低于""不足""多于"不含本数。 第七十六条 本规则所称公告、通知或股东会补充通知，是指在符合中国证监会规定条件的媒体和上海 证券交易所网站上公布有关信息披露内容。 第七十七条 本规则为《公司章程》附则。本规则未尽事宜，或者与有关法律、法规、规范性文件的强 制性规定或《公司章程》的要求相抵触的，按有关法律、法规、规范性文件、《公司章程》的规定执 行。 第七十八条 本规则的解释权属于董事会。 第七十九条 本规则由董事会制定、经股东会批准之日起生效，修改时亦同。 辽宁成大生物股份有限公司 董事会 2026年 1月26日 证券代码：688739 证券简称：成大生物 公告编号：2026-004 辽宁成大生物股份有限公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （三）本次业绩预告未经注册会计师审 ...

Group 1 - The animal health sector experienced a significant increase of 5.61% on January 26, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the animal health sector showed notable price increases, with Yongshun Biological rising by 27.18% to a closing price of 11.79, and Huisheng Biological increasing by 20.01% to 32.62 [1] Group 2 - The animal health sector saw a net inflow of 437 million yuan from institutional investors, while retail investors experienced a net outflow of 307 million yuan [2] - The trading volume for Yongshun Biological reached 292,600 shares, contributing to a total transaction value of 328 million yuan [1][2] - The stock performance of various companies in the sector varied, with some experiencing significant gains while others faced declines in retail investment [3]

Group 1 - The animal vaccine concept sector rose by 4.89%, ranking fifth among concept sectors, with 18 stocks increasing in value, including Yongshun Biological, Dongfang Biological, and Haili Biological, which saw increases of 27.18%, 12.36%, and 7.18% respectively [1] - The animal vaccine sector attracted a net inflow of 229 million yuan from main funds, with 14 stocks receiving net inflows, and 5 stocks exceeding 30 million yuan in net inflow. The leading stock in net inflow was Biological Shares, with a net inflow of 100 million yuan [2] - The top three stocks by net inflow ratio were KQ Biological, Tiankang Biological, and Biological Shares, with net inflow ratios of 14.32%, 12.76%, and 9.87% respectively [3] Group 2 - The animal vaccine sector's inflow ranking included Biological Shares with a 4.50% increase and a turnover rate of 5.08%, followed by Dabeinong with a 2.70% increase and a turnover rate of 6.49% [4] - Other notable stocks included Jinhai Biological with a 5.95% increase and a turnover rate of 9.28%, and Tiankang Biological with a 1.99% increase and a turnover rate of 2.95% [5] - Stocks that experienced declines included Hengtong Holdings with a decrease of 2.59% and a turnover rate of 5.31%, and Luoniushan with a decrease of 1.86% and a turnover rate of 3.43% [5]

Group 1 - The A-share influenza vaccine sector is experiencing a strong performance, with companies such as Da'an Gene, Hualan Biological Engineering, and Zhijiang Biological reaching their daily limit up [1] - Yongshun Biological has seen an increase of over 10%, indicating positive market sentiment towards the sector [1] - Other companies in the sector, including Dongfang Biological, Biological Shares, Zhongsheng Pharmaceutical, Yiling Pharmaceutical, and Rhine Biological, are also witnessing gains [1]

Market Overview - The animal health sector experienced a decline of 0.32% on January 23, with BioShares leading the drop [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (920275) with a closing price of 9.68, up 4.09% on a trading volume of 36,300 shares and a turnover of 34.72 million yuan [1] - Haili Biological (603718) closed at 6.55, up 1.24% with a trading volume of 95,100 shares and a turnover of 61.91 million yuan [1] - Deyu Biological (920970) closed at 8.44, up 1.20% with a trading volume of 19,200 shares and a turnover of 16.26 million yuan [1] - Conversely, BioShares (600201) closed at 17.35, down 1.42% with a trading volume of 315,700 shares and a turnover of 551 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 142 million yuan from institutional investors, while retail investors experienced a net inflow of 124 million yuan [2][3] - Specific stock capital flows included: - Zhongmu Shares (600195) with a net inflow of 14.27 million yuan from institutional investors [3] - Qudongli (920275) had a net inflow of 2.44 million yuan from retail investors [3] - Deyu Biological (920970) faced a net outflow of 1.04 million yuan from institutional investors [3]